Literature DB >> 9728539

Human antibodies elicited by a pneumococcal vaccine express idiotypic determinants indicative of V(H)3 gene segment usage.

J Abadi1, J Friedman, R A Mageed, R Jefferis, M C Rodriguez-Barradas, L Pirofski.   

Abstract

Human immunodeficiency virus (HIV)-infected persons manifest decreased antibody responses to pneumococcal polysaccharide vaccines. Since human antibody responses to polysaccharides are often restricted, the molecular structure of antibodies elicited by a 23-valent pneumococcal vaccine was analyzed. Anti-idiotypic reagents were used to detect V(H)1, V(H)3, and V(H)4 gene usage by antibodies to pneumococcal capsular polysaccharides in HIV-uninfected and HIV-infected subjects by ELISA. HIV-uninfected persons generated beta-mercaptoethanol-sensitive and -resistant antibodies to pneumococcal capsular polysaccharides expressing V(H)3 determinants recognized by the D12, 16.84, and B6 monoclonal antibodies; antibodies expressing V(H)1 determinants were not detected, and V(H)4 determinants were expressed by beta-mercaptoethanol-sensitive antibodies only; and HIV-infected subjects had significantly lower capsular polysaccharide-specific and V(H)3-positive antibody responses. These findings confirm decreased antibody responses to pneumococcal vaccination in HIV-infected persons and suggest that their poor responses may result from HIV-associated depletion of restricted B cell subsets.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9728539     DOI: 10.1086/515369

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  19 in total

1.  Combinatorial library cloning of human antibodies to Streptococcus pneumoniae capsular polysaccharides: variable region primary structures and evidence for somatic mutation of Fab fragments specific for capsular serotypes 6B, 14, and 23F.

Authors:  A H Lucas; K D Moulton; V R Tang; D C Reason
Journal:  Infect Immun       Date:  2001-02       Impact factor: 3.441

2.  Pneumococcal capsular polysaccharide vaccine-mediated protection against serotype 3 Streptococcus pneumoniae in immunodeficient mice.

Authors:  Haijun Tian; Avi Groner; Marianne Boes; Liise-anne Pirofski
Journal:  Infect Immun       Date:  2007-01-12       Impact factor: 3.441

3.  A peptide mimotope of type 8 pneumococcal capsular polysaccharide induces a protective immune response in mice.

Authors:  Ulrike K Buchwald; Andrew Lees; Michael Steinitz; Liise-Anne Pirofski
Journal:  Infect Immun       Date:  2005-01       Impact factor: 3.441

4.  Cryptococcus neoformans-reactive and total immunoglobulin profiles of human immunodeficiency virus-infected and uninfected Ugandans.

Authors:  Krishanthi Subramaniam; Neil French; Liise-Anne Pirofski
Journal:  Clin Diagn Lab Immunol       Date:  2005-10

5.  Antibody response to Cryptococcus neoformans capsular polysaccharide glucuronoxylomannan in patients after solid-organ transplantation.

Authors:  Ziba Jalali; Lucky Ng; Nina Singh; Liise-anne Pirofski
Journal:  Clin Vaccine Immunol       Date:  2006-07

6.  Human monoclonal antibodies against Pseudomonas aeruginosa lipopolysaccharide derived from transgenic mice containing megabase human immunoglobulin loci are opsonic and protective against fatal pseudomonas sepsis.

Authors:  S Hemachandra; K Kamboj; J Copfer; G Pier; L L Green; J R Schreiber
Journal:  Infect Immun       Date:  2001-04       Impact factor: 3.441

7.  V(H)3 antibody response to immunization with pneumococcal polysaccharide vaccine in middle-aged and elderly persons.

Authors:  Jose A Serpa; Josemon Valayam; Daniel M Musher; Roger D Rossen; Liise-anne Pirofski; Maria C Rodriguez-Barradas
Journal:  Clin Vaccine Immunol       Date:  2011-01-12

8.  Immunogenicity and efficacy of Cryptococcus neoformans capsular polysaccharide glucuronoxylomannan peptide mimotope-protein conjugates in human immunoglobulin transgenic mice.

Authors:  Robert W Maitta; Kausik Datta; Andrew Lees; Shelley Sims Belouski; Liise-anne Pirofski
Journal:  Infect Immun       Date:  2004-01       Impact factor: 3.441

9.  Protective and nonprotective human immunoglobulin M monoclonal antibodies to Cryptococcus neoformans glucuronoxylomannan manifest different specificities and gene use profiles.

Authors:  Robert W Maitta; Kausik Datta; Qing Chang; Robin X Luo; Bradley Witover; Krishanthi Subramaniam; Liise-anne Pirofski
Journal:  Infect Immun       Date:  2004-08       Impact factor: 3.441

10.  VH3 gene usage in neutralizing human antibodies specific for the Entamoeba histolytica Gal/GalNAc lectin heavy subunit.

Authors:  Hiroshi Tachibana; Katsuomi Watanabe; Xun-Jia Cheng; Hideo Tsukamoto; Yoshimasa Kaneda; Tsutomu Takeuchi; Seiji Ihara; William A Petri
Journal:  Infect Immun       Date:  2003-08       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.